Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Roche executive says Alzheimer's drug price will be competitive

Stock MarketsNov 10, 2021 10:11AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: A logo of Swiss pharmaceutical company Roche in Rotkreuz, Switzerland, April 12, 2012.REUTERS/Michael Buholzer

By Deena Beasley

(Reuters) - Roche Holding AG (OTC:RHHVF), still months away from seeking regulatory approval of its experimental Alzheimer's drug, is already taking aim at rival Biogen Inc (NASDAQ:BIIB)'s Aduhelm, saying that its medication would be priced competitively.

Bill Anderson, head of pharmaceuticals at Roche, did not provide pricing details for the company's treatment for the lethal brain-wasting disease, but indicated in an interview that it could be priced below Aduhelm's $56,000-a-year cost. Anderson said Roche has taken similar action in the past, including for multiple sclerosis drug Ocrevus, which was launched at a price 30% below the standard of care.

When it launched in June, Biogen's drug became the first approved medication that targets one of the changes in the brain that occurs with Alzheimer's. But Aduhelm sales have stalled as Medicare, the U.S. government healthcare program for people over age 65, evaluates coverage.

The delay has opened up opportunities for rivals such as Roche whose drugs are still many months away from U.S. Food and Drug Administration review and their approval is uncertain.

Anderson said Roche has priced new therapies in the United States "at or below the prices of things we replace ... even though we had superior results."

Roche, Biogen and other drugmakers are due to present data this week at the annual Clinical Trials on Alzheimer's Disease conference in Boston.

Roche's Alzheimer's candidate gantenerumab, like Aduhelm, is designed to remove amyloid plaques from the brains of people diagnosed with the disease. Roche has said it will wait for pivotal trial results, due in the second half of 2022, before seeking regulatory review.

Anderson told Reuters that Roche aims to show "unequivocal data on efficacy."

The FDA approved Biogen's drug based on evidence that it reduces amyloid brain plaques, a likely contributor to Alzheimer's, rather than proof that it slows the disease's progression.

Eli Lilly & Co (NYSE:LLY) has begun a rolling FDA application for its own experimental Alzheimer's drug based on evidence of its plaque-removing ability. Lilly's drug could get U.S. approval by the second half of next year.

Medicare expects to issue a final decision in April on its reimbursement policy, which will apply to all plaque-reducing agents.

Biogen posted third-quarter Aduhelm sales of just $300,000, far below the $11 million Wall Street had expected. Some neurology centers using the drug have said the company is providing Aduhelm, given as a monthly infusion, free of charge while the insurance claims process is worked out.

(This story corrects second paragraph to clarify that Roche launched multiple sclerosis drug Ocrevus at 30% discount.)

Roche executive says Alzheimer's drug price will be competitive
 

Related Articles

Airline easyJet cancels more than 200 flights
Airline easyJet cancels more than 200 flights By Reuters - May 28, 2022 3

LONDON (Reuters) - Low-cost carrier easyJet (LON:EZJ) is to cancel more than 200 flights over the next 10 days due to airport delays and other restrictions, disrupting travel...

China's first residential REITs to be launched
China's first residential REITs to be launched By Reuters - May 28, 2022

SHANGHAI (Reuters) - China's first public real estate investment trusts (REITs) based on residential properties will be launched soon, as regulators step up efforts to channel...

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email